Kardiotoksiske effekter av trastuzumab

Tidsskrift for den Norske Laegeforening

Volumn 131, Issue 22, 2011, Pages 2239-2241

  Hysing, Jan ^a   Wist, Erik ^b  

^a Medisinsk Avdeling   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARDIOTOXIN; MONOCLONAL ANTIBODY; TRASTUZUMAB;

BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; FEMALE; HEART FAILURE; HUMAN; METASTASIS; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOTOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 84856032571     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.10.0862     Document Type: Article

References (25)

1. Kaldager M, Zelen M, Langmark F et al. Effect of breast-cancer screening on mortality in Norway. N Engl J Med 2010; 363: 1203 - 10.
2. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783 - 92.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659 - 72.
4. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673 - 84.
5. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859 - 65.
6. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710 - 7.
7. Ryberg M, Nielsen D, Cortese G et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008; 100: 1058 - 67.
8. Tveteraas IH, Lundgren S, Bruserud Ø, et al. Antibiotika med cytostatisk effekt. I: Dahl O, Lehne G, Baksaas I et al, red. Medikamentell kreftbehandling Cytostatikahåndboken 7. utg. Oslo: Farmakologisk institutt, Det medisinske fakultet, Universitetet i Oslo, 2009.
9. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737 - 44.
10. Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659 - 71.
11. Levy WC, Mozaffarian D, Linker DT et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113: 1424 - 33.
12. Chien KR. Herceptin and the heart-a molecular modifier of cardiac failure. N Engl J Med 2006; 354: 789 - 90.
13. Felleskatalogen over farmasøytiske spesialpreparater. Produktomtale: Herceptin. Oslo: felleskatalogen. no, 2010.
14. Jones AL, Barlow M, Barrett-Lee PJ et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009; 100: 684 - 92.
15. Norsk Bryst Cancer Gruppe (NBCG). www.nbcg.no/adjuvant_behandling/5.kontroll.av.hj.57-1.pd (11.10.2011).
16. Guglin M, Cutro R, Mishkin JD. Trastuzumabinduced cardiomyopathy. J Card Fail 2008; 14: 437 - 44.
17. Smith I, Procter M, Gelber RD et al; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29 - 36.
18. Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006; 24: 4107 - 15.
19. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749 - 54.
20. Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26: 1231 - 8.
21. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820 - 6.
22. Procter M, Suter TM, de Azambuja E et al. Longerterm assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010; 28: 3422 - 8.
23. Russell SD, Blackwell KL, Lawrence J et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010; 28: 3416 - 21.
24. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48: 2258 - 62.
25. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474 - 81.